L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Results

Abstract

L-deprenyl did not have a measurable impact on behavior or cognitive function over a 2-month period in this group of subjects with mild DAT.

L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Results of a 15–Month Trial

“…We have previously reported the interim results of our study after 2 months of treatment with L‐deprenyl 36 . Unlike these prior reports, the interim (2 month) results of this study detected no evidence for any L‐deprenyl effect on any clinical or neuropsychological measure 36 …”

“…We have previously reported the interim results of our study after 2 months of treatment with L-de-~r e n y 1 .~~ Unlike these prior reports, the interim (2 month) results of this study detected no evidence for any L-deprenyl effect on any clinical or neuropsychological measure. 36 The intent of this 15-month evaluation was to examine what effect L-deprenyl might have over a longer period of time in subjects with DAT. The only measure that showed any evidence of a drug effect was, interestingly enough, the total score on the BPRS.…”

Isoniazid improves cognitive performance, clears Aβ plaques, and protects dendritic synapses in APP/PS1 transgenic mice

“…In addition, our result showed that INH treatment considerably inhibited Mao-b activity in APP/PS1 mice. Interestingly, the Mao-b inhibitors, such as selegiline, have been shown to possess the beneficial effects on cognitive impairment in AD patients ( Burke et al, 1993 ; Tolbert and Fuller, 1996 ; Filip and Kolibás, 1999 ). Therefore the inhibitory effect of INH on Mao-b may also contribute to the therapeutic effect on memory impairment in APP/PS1 mice.…”

Recent Advances: Clinical pharmacology and therapeutics

“…Drugs as diverse as the non-steroidal anti-inflammatory indomethacin,20 the monoamine oxidase inhibiter selegiline,21 and the peptidergic nootropic drug cerebrolysin22 have been investigated in short term studies in Alzheimer's disease, but the rationale for their use is not clear. An intriguing observation relates to the effects of nicotine in Alzheimer's disease.…”